MANUFACTURERS

Ultima Pharma Pharmacom Labs Para Pharma Pharmaqo Nakon Medical Dragon Pharma Euro-Pharmacies Deus Medical Hilma Biocare Somatrop-Lab Sixpex Beligas Xeno Labs Stealth Labs Abbott Abdi Ibrahim Aburaihan Aksufarma Ilac San Allergan Ali Raif Alium Anke Bio Amgen Apex Pharma Aptissen Astellas AstraZeneca Ajanta Pharma Alkem Laboratories Alto Aurochem Laboratories Argis Aspen Assos Atabay Aventis Ayset Balkan Pharmaceuticals Banford Bayer Bayer Zydus Pharma Becton Dickinson Belmed Berko Berlin-Chemie Besins Bilim Bioamino Labs BioTeq Labs Bharat Serums And Vaccines Boehringer Cadila Pharma Canada Peptides Centurion Laboratories Cipla Concern Pharma Conventional Syringes Daewoong Daiichi Sankyo Darnitsa Deva Dharam Distributors Dong-A Dosfarm Drogsan Drooc Pharma Eczacıbaşı Embil Europe GT Evalar Farmak Ferring Fidia Fortune Health Care Galenika German Remedies Genetic Pharma Genopharm GenSci Generics Grindex GSK HAB Pharma Hansel Healing Pharma Hemat Himalaya Hubio Pharm Hygene Pharma IBSA Ice Pharma Innventa Pharm Ipsen Intas Biopharmaceuticals Iran Hormone Jelfa Johnlee Pharmaceuticals Kanonpharma Kocak Farma Knoll Healthcare KRKA Liba Lilly Livzon Lizhu Bio Macleods Meda Pharma Menarini Merck MSD Mustafa Nevzat Natco Pharma Neutec Nobel Novartis Novo Nordisk Odin Anabolics Omstal Pharma Organon Orion Corp Orva Ozon Parex Pharmacia & Upjohn Pharmacy Turkish Pfizer Pliva Ranbaxy RJ Bio Roche RSM Pharma Satan Pharma Sandoz Sanofi Sanovel Schonen Servier SFM Signature Spectrum Pharma Sopharma Sun Pharma Sunrise Remedies Singani Pharma Takeda Teva Pharmaceutical UCB Vipro Lifescience Xantis Pharma Zerox Pharma Zdorovje Zee Laboratories Zhengzhou Pharma Zydus Cadila Healthcare

Wholesale

Survodutide

Shipping options
$100.00
Quanity:
Log in to subscribe for notifications
Shipping options

Characteristics

Active Substance
FORM
1 vial x 10 mg
Manufacturer

Description

SURVODUTIDE - DRAGON PHARMA

 

1 vial x 10 mg

 

Survodutide
Survodutide (BI-456906) is currently under investigation for its efficacy in treating renal failure, non-alcoholic steatohepatitis (NASH), liver fibrosis, type 2 diabetes, and obesity. Administered once weekly via subcutaneous or parenteral routes, Survodutide acts through the activation of the glucagon-like peptide 1 receptor (GLP-1R). This receptor-mediated mechanism plays a crucial role in its potential therapeutic applications for metabolic and liver diseases.


 

Customer Reviews


Back to top